Results 21 to 30 of about 350,979 (277)

Origin of the mixed-order transition in multiplex networks: the Ashkin-Teller model

open access: yes, 2014
Recently, diverse phase transition (PT) types have been obtained in multiplex networks, such as discontinuous, continuous, and mixed-order PTs. However, they emerge from individual systems, and there is no theoretical understanding of such PTs in a ...
Hwang, S.   +3 more
core   +1 more source

Incidence of wrong-site surgery list errors for a 2-year period in a single national health service board [PDF]

open access: yes, 2017
Introduction: Wrong-site/side surgical "never events" continue to cause considerable harm to patients, healthcare professionals, and organizations within the United Kingdom.
Bowie, Paul   +3 more
core   +1 more source

Assessment bioaccumulation factor (BAF) of methyl siloxanes in crucian carp (Carassius auratus) around a siloxane production factory

open access: yesEcotoxicology and Environmental Safety, 2021
Methyl siloxanes are identified as emerging persistent toxic compounds and the ecological environment risks of these compounds have been caused of great concern worldwide.
Weijun Guo   +6 more
doaj   +1 more source

Patient‐Level Barriers and Facilitators to Inpatient Physical Therapy in Adolescents and Young Adults With a Hematological Malignancy: A Qualitative Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Despite their increased risk for functional impairment resulting from cancer and its treatments, few adolescents and young adults (AYAs) with a hematological malignancy receive the recommended or therapeutic dose of exercise per week during inpatient hospitalizations.
Jennifer A. Kelleher   +8 more
wiley   +1 more source

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer [PDF]

open access: yes, 2018
Background: INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12), a synthetic DNA immunotherapy, was assessed for safety, immunogenicity and efficacy in biochemically recurrent prostate cancer patients (pts).
Appleman, L. J.   +19 more
core   +1 more source

The PT-symmetric brachistochrone problem, Lorentz boosts and non-unitary operator equivalence classes

open access: yes, 2008
The PT-symmetric (PTS) quantum brachistochrone problem is reanalyzed as quantum system consisting of a non-Hermitian PTS component and a purely Hermitian component simultaneously. Interpreting this specific setup as subsystem of a larger Hermitian system,
A. Dijksma   +17 more
core   +1 more source

Exercise Interventions in Children, Adolescents and Young Adults With Paediatric Bone Tumours—A Systematic Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Bone tumours present significant challenges for affected patients, as multimodal therapy often leads to prolonged physical limitations. This is particularly critical during childhood and adolescence, as it can negatively impact physiological development and psychosocial resilience.
Jennifer Queisser   +5 more
wiley   +1 more source

Exosomes derived from mesenchymal stem cells enhance radiotherapy-induced cell death in tumor and metastatic tumor foci

open access: yesMolecular Cancer, 2018
Background We have recently shown that radiotherapy may not only be a successful local and regional treatment but, when combined with MSCs, may also be a novel systemic cancer therapy.
Virgínea de Araujo Farias   +12 more
doaj   +1 more source

Microwave-Assisted Formation of Ternary Inclusion Complex of Pterostilbene

open access: yesPharmaceuticals, 2023
Pterostilbene (PTS) is a naturally occurring phytoalexin. PTS displays limited water solubility, which consequently results in its diminished oral bioavailability.
Yousef A. Bin Jardan   +4 more
doaj   +1 more source

NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss [PDF]

open access: yes, 2018
Background: The NCI-MATCH trial is the largest national study (1173 sites) for ptswith relapsed/ refractory solid tumors, lymphomas and myeloma, which assigns tar-geted therapies based on individual tumor molecular alterations detected using theadapted ...
Arteaga, C.   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy